Literature DB >> 8350100

Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease.

M B Schapiro1, P Pietrini, C L Grady, M J Ball, C DeCarli, A Kumar, J A Kaye, J V Haxby.   

Abstract

Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal regions has been shown in Alzheimer's disease (AD). The specificity of these findings for this disease state is uncertain. We repeatedly measured rCMRglc with positron emission tomography and [18F]2-fluoro-2-deoxy-D-glucose in the resting state in a 68 year old man with slowly progressive dementia who, during life, was initially diagnosed as having dementia of the Alzheimer type, then Parkinson disease with dementia, but was found to have only Parkinson's disease at necropsy. Metabolic ratios (rCMRglc/mean grey CMRglc) were significantly (p < 0.05) reduced in parietal and temporal regions, as well as in the prefrontal and premotor areas. This pattern was similar in regional distribution and magnitude of the defect to that seen in patients with probable AD. These results suggest that reductions of glucose metabolism in association neocortex in AD are not specific to the disease process, but may be related to the dementia state.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350100      PMCID: PMC1015138          DOI: 10.1136/jnnp.56.8.859

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  26 in total

1.  Cerebral blood flow in dementia.

Authors:  V C Hachinski; L D Iliff; E Zilhka; G H Du Boulay; V L McAllister; J Marshall; R W Russell; L Symon
Journal:  Arch Neurol       Date:  1975-09

2.  The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

Authors:  L Sokoloff; M Reivich; C Kennedy; M H Des Rosiers; C S Patlak; K D Pettigrew; O Sakurada; M Shinohara
Journal:  J Neurochem       Date:  1977-05       Impact factor: 5.372

3.  Cortical cholinergic deficit in mentally impaired Parkinsonian patients.

Authors:  R H Perry; B E Tomlinson; J M Candy; G Blessed; J F Foster; C A Bloxham; E R Perry
Journal:  Lancet       Date:  1983-10-01       Impact factor: 79.321

4.  The morphological basis of dementia in Parkinson's disease.

Authors:  M J Ball
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

5.  Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 years.

Authors:  R Duara; R A Margolin; E A Robertson-Tchabo; E D London; M Schwartz; J W Renfrew; B J Koziarz; M Sundaram; C Grady; A M Moore
Journal:  Brain       Date:  1983-09       Impact factor: 13.501

6.  Alternative formula for glucose utilization using labeled deoxyglucose.

Authors:  R A Brooks
Journal:  J Nucl Med       Date:  1982-06       Impact factor: 10.057

7.  Bitemporal hypometabolism in Creutzfeldt-Jakob disease measured by positron emission tomography with [18F]-2-fluorodeoxyglucose.

Authors:  R P Friedland; S B Prusiner; W J Jagust; T F Budinger; R L Davis
Journal:  J Comput Assist Tomogr       Date:  1984-10       Impact factor: 1.826

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

9.  Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method.

Authors:  D E Kuhl; E J Metter; W H Riege
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

10.  Pathological basis for neurotransmitter changes in Parkinson's disease.

Authors:  D M Mann; P O Yates
Journal:  Neuropathol Appl Neurobiol       Date:  1983 Jan-Feb       Impact factor: 8.090

View more
  4 in total

Review 1.  A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile.

Authors:  Konstantine K Zakzanis; Simon J Graham; Zachariah Campbell
Journal:  Neuropsychol Rev       Date:  2003-03       Impact factor: 7.444

Review 2.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

3.  Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases.

Authors:  Yu Iwabuchi; Tohru Shiga; Masashi Kameyama; Raita Miyazawa; Morinobu Seki; Daisuke Ito; Hiroyuki Uchida; Hajime Tabuchi; Masahiro Jinzaki
Journal:  Mol Imaging Biol       Date:  2022-06-14       Impact factor: 3.488

Review 4.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.